These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes. Lee HJ; Jun RM; Cho MS; Choi KR Cutan Ocul Toxicol; 2015; 34(3):195-202. PubMed ID: 25265260 [TBL] [Abstract][Full Text] [Related]
15. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Goldberg I; Graham SL; Crowston JG; d'Mellow G; Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488 [TBL] [Abstract][Full Text] [Related]
16. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study. Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425 [TBL] [Abstract][Full Text] [Related]
17. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension]. Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372 [TBL] [Abstract][Full Text] [Related]
18. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review. Asiedu K; Abu SL J Curr Ophthalmol; 2019 Mar; 31(1):8-15. PubMed ID: 30899840 [TBL] [Abstract][Full Text] [Related]